Want to see IN:SPARC full AI Analyst Report?
Top Page
Sun Pharma Advanced Research Co. Ltd.
(SPARC)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹172.00
▼(-20.52% Downside)
Action:Reiterated
Date:08/26/26
The score is held back primarily by weak financial quality (ongoing negative operating/free cash flow despite the FY2026 earnings rebound) and bearish technical momentum (price below key moving averages with negative MACD). A very low P/E provides some offsetting support on valuation.
Positive Factors
FY2026 revenue and profit rebound
The reported FY2026 rebound materially improves the company’s near-term earnings base and demonstrates that its development activities can generate substantial financial outcomes. If the improvement reflects repeatable monetization rather than a one-off driver, it could support reinvestment in the pipeline and strengthen operating scale.
Negative Factors
Persistent negative cash generation
Continued operating and free-cash-flow deficits show that the FY2026 earnings rebound has not translated into internal cash generation. Ongoing cash burn can require additional funding, constrain investment in clinical development, and reduce the company’s ability to absorb delays or weaker monetization outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
FY2026 revenue and profit rebound
The reported FY2026 rebound materially improves the company’s near-term earnings base and demonstrates that its development activities can generate substantial financial outcomes. If the improvement reflects repeatable monetization rather than a one-off driver, it could support reinvestment in the pipeline and strengthen operating scale.
Read all positive factors
Sun Pharma Advanced Research Co. Ltd. (SPARC) vs. iShares MSCI India ETF (INDA)
Market Cap
₹59.24B
Dividend YieldN/A
Average Volume (3M)77.02K
Price to Earnings (P/E)3.7
Beta (1Y)1.91
Revenue Growth2855.80%
EPS GrowthN/A
CountryIN
Employees279
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)48.81
Shares Outstanding324,521,600
10 Day Avg. Volume66,812
30 Day Avg. Volume77,018
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.78
Price to Sales (P/S)1.98
P/FCF Ratio-12.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sun Pharma Advanced Research Co. Ltd. Business Overview & Revenue Model
Company Description
Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm established in Mumbai, India, in 2006 and operating as a subsidiary of Shanghvi Finance Private Limited, is globally committed to the discovery and advancement of innov...
How the Company Makes Money
SPARC primarily makes money by monetizing its drug-development pipeline and R&D capabilities rather than by selling large volumes of finished medicines directly. Key revenue streams include: (1) Out-licensing and collaboration income: SPARC can gr...
Sun Pharma Advanced Research Co. Ltd. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.09B | 18.79B | 717.70M | 755.45M | 2.39B | 1.37B |
| Gross Profit | 17.81B | 17.27B | 486.50M | -1.24B | 821.21M | 105.52M |
| EBITDA | 16.04B | 15.99B | -3.23B | -3.73B | -2.03B | -1.80B |
| Net Income | 15.84B | 15.53B | -3.43B | -3.87B | -2.23B | -2.03B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 21.71B | 3.36B | 5.15B | 8.30B | 2.80B |
| Cash, Cash Equivalents and Short-Term Investments | 11.55M | 26.20M | 19.60M | 1.57B | 4.07B | 128.89M |
| Total Debt | 0.00 | 5.59B | 2.69B | 611.51M | 156.70M | 792.14M |
| Total Liabilities | -13.39B | 8.32B | 5.52B | 3.89B | 3.17B | 2.49B |
| Stockholders Equity | 13.39B | 13.39B | -2.17B | 1.26B | 5.13B | 312.26M |
Cash Flow | ||||||
| Free Cash Flow | -1.39B | -2.97B | -3.71B | -4.56B | -845.10M | -2.41B |
| Operating Cash Flow | -1.16B | -2.73B | -3.60B | -4.29B | -691.20M | -2.08B |
| Investing Cash Flow | -231.00M | -235.30M | 1.58B | 3.92B | -5.48B | -291.67M |
| Financing Cash Flow | 1.38B | 2.96B | 1.99B | 424.05M | 6.17B | 2.29B |
Sun Pharma Advanced Research Co. Ltd. Technical Analysis
Neutral
216.40
Price Trends
193.89
Negative
210.60
Negative
177.20
Positive
Market Momentum
-5.43
Positive
44.26
Neutral
44.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SPARC, the sentiment is Neutral. The current price of 216.4 is above the 20-day moving average (MA) of 187.52, above the 50-day MA of 193.89, and above the 200-day MA of 177.20, indicating a neutral trend. The MACD of -5.43 indicates Positive momentum. The RSI at 44.26 is Neutral, neither overbought nor oversold. The STOCH value of 44.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SPARC.
Sun Pharma Advanced Research Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹256.80B | 51.47 | ― | 0.17% | 78.33% | 182.61% | |
61 Neutral | ₹182.42B | 112.81 | ― | 1.68% | 41.24% | -70.51% | |
56 Neutral | ₹309.94B | -98.23 | ― | 0.07% | 9.43% | -767.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹150.58B | 42.44 | ― | 0.53% | 16.27% | -23.50% | |
50 Neutral | ₹59.24B | 3.74 | ― | ― | 2855.80% | ― | |
43 Neutral | ₹75.91B | -18.40 | ― | 11.14% | 17.26% | -68.16% |
* General Sector Average
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
183.25
46.20
33.71%
IN:JUBLPHARMA
Jubilant Pharmova Limited
942.40
-171.43
-15.39%
IN:NEULANDLAB
Neuland Laboratories Ltd.
19,275.95
3,136.98
19.44%
IN:PPLPHARMA
Piramal Pharma Limited
230.60
28.70
14.21%
IN:SUVEN
Suven Life Sciences Limited
264.80
72.00
37.34%
IN:COHANCE
Suven Pharmaceuticals Ltd.
481.35
-297.35
-38.19%
Sun Pharma Advanced Research Co. Ltd. Corporate Events
Sun Pharma Advanced Research Wins Rs 27.51 Crore CENVAT Refund Case
Oct 4, 2026
Sun Pharma Advanced Research Company Limited has reported a favorable outcome in a key indirect tax dispute before the Customs, Excise Service Tax Appellate Tribunal in Mumbai. The tribunal has upheld a 2018 appellate order granting the company a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.